Assignee

MACROGENICS INC

US86 patents

Top patents by PatentIndex Score

US7521542B2Apr 21, 2009

Humanized FcγRIIB-specific antibodies and methods of use thereof

MACROGENICS INC105 citations99

US8003774B2Aug 23, 2011

Identification and engineering of antibodies with variant Fc regions and methods of using same

MACROGENICS INC96 citations98

US7960512B2Jun 14, 2011

Identification and engineering of antibodies with variant Fc regions and methods of using same

MACROGENICS INC161 citations98

US7786270B2Aug 31, 2010

Identification and engineering of antibodies with variant Fc regions and methods of using same

MACROGENICS INC361 citations98

US7351803B2Apr 1, 2008

CD16A binding proteins and use for the treatment of immune disorders

MACROGENICS INC78 citations98

US8044180B2Oct 25, 2011

FcγRIIB specific antibodies and methods of use thereof

MACROGENICS INC52 citations97

US7112439B2Sep 26, 2006

Dual expression vector system for antibody expression in bacterial and mammalian cells

MACROGENICS INC78 citations97

US9822181B2Nov 21, 2017

Bi-specific monovalent diabodies that are capable of binding CD123 and CD3, and uses thereof

MACROGENICS INC62 citations96

US10577422B2Mar 3, 2020

PD-1-binding molecules and methods of use thereof

MACROGENICS INC19 citations94

US10160806B2Dec 25, 2018

Covalently bonded diabodies having immunoreactivity with PD-1 and LAG-3, and methods of use thereof

MACROGENICS INC18 citations94

US7572456B2Aug 11, 2009

Humanized antibodies against West Nile Virus and therapeutic and prophylactic uses thereof

MACROGENICS INC21 citations93

US10647768B2May 12, 2020

Multi-chain polypeptide-containing tri-specific binding molecules

MACROGENICS INC19 citations92

US10131713B2Nov 20, 2018

HER2/neu-specific antibodies and methods of using same

MACROGENICS INC10 citations92

US9243069B2Jan 26, 2016

HER2/neu-specific antibodies and methods of using the same

MACROGENICS INC13 citations92

US8951517B2Feb 10, 2015

Identification and engineering of antibodies with variant Fc regions and methods of using same

MACROGENICS INC19 citations92

US7838635B2Nov 23, 2010

CD16A binding proteins and use for the treatment of immune disorders

MACROGENICS INC17 citations92

US7718774B2May 18, 2010

TES7 and antibodies that bind thereto

MACROGENICS INC32 citations92

US7618628B2Nov 17, 2009

CD16A binding proteins and use for the treatment of immune disorders

MACROGENICS INC22 citations92

US7632497B2Dec 15, 2009

Engineering Fc Antibody regions to confer effector function

MACROGENICS INC217 citations90

US11623959B2Apr 11, 2023

PD-1-binding molecules and methods of use thereof

MACROGENICS INC6 citations84

US11028183B2Jun 8, 2021

HER2/neu-specific antibodies and methods of using same

MACROGENICS INC3 citations84

US10711069B2Jul 14, 2020

Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting

MACROGENICS INC7 citations84

US10633440B2Apr 28, 2020

Multi-chain polypeptide-containing tri-specific binding molecules that specifically bind to multiple cancer antigens

MACROGENICS INC11 citations84

US10150812B2Dec 11, 2018

CD3-binding molecules capable of binding to human and non-human CD3

MACROGENICS INC9 citations84

US10093738B2Oct 9, 2018

Covalent diabodies and uses thereof

MACROGENICS INC7 citations84

US9708408B2Jul 18, 2017

Methods for the treatment of disease using immunoglobulins having Fc Regions with altered affinities for FcγRactivating and FcγRinhibiting

MACROGENICS INC9 citations84

US9695236B2Jul 4, 2017

BCR-complex-specific antibodies and methods of using same

MACROGENICS INC11 citations84

US9487587B2Nov 8, 2016

Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof

MACROGENICS INC9 citations84

US9469692B2Oct 18, 2016

HER2/neu-specific antibodies and methods of using same

MACROGENICS INC8 citations84

US8993730B2Mar 31, 2015

BCR-complex-specific antibodies and methods of using same

MACROGENICS INC10 citations84

US10787521B2Sep 29, 2020

Bi-specific monovalent diabodies that are capable of binding CD123 and CD3, and uses thereof

MACROGENICS INC7 citations83

US9896508B2Feb 20, 2018

Antibodies reactive with B7-H3 and uses thereof

MACROGENICS INC8 citations83

US9714295B2Jul 25, 2017

Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof

MACROGENICS INC6 citations83

US9714296B2Jul 25, 2017

Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof

MACROGENICS INC7 citations83

US9441049B2Sep 13, 2016

Antibodies reactive with B7-H3 and uses thereof

MACROGENICS INC10 citations83

US7906327B2Mar 15, 2011

Dual expression vector system for antibody expression in bacterial and mammalian cells

MACROGENICS INC9 citations83

US9908938B2Mar 6, 2018

Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof

MACROGENICS INC6 citations82

US7776328B2Aug 17, 2010

Antibodies that bind to EphA2 and methods of use thereof

MACROGENICS INC6 citations74

US11858991B2Jan 2, 2024

LAG-3-binding molecules and methods of use thereof

MACROGENICS INC2 citations73

US11685781B2Jun 27, 2023

Variant CD3-binding domains and their use in combination therapies for the treatment of disease

MACROGENICS INC4 citations73

US11384149B2Jul 12, 2022

Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof

MACROGENICS INC4 citations73

US11111299B2Sep 7, 2021

CD3-binding molecules capable of binding to human and non-human CD3

MACROGENICS INC3 citations73

US11098119B2Aug 24, 2021

Covalently bonded diabodies having immunoreactivity with PD-1 and LAG-3, and methods of use thereof

MACROGENICS INC2 citations73

US11072653B2Jul 27, 2021

LAG-3-binding molecules and methods of use thereof

MACROGENICS INC4 citations73

US10633443B2Apr 28, 2020

Bi-specific monovalent diabodies that are capable of binding CD19 and CD3, and uses thereof

MACROGENICS INC3 citations73

US10479831B2Nov 19, 2019

BCR-complex-specific antibodies and methods of using same

MACROGENICS INC1 citations73

US10344092B2Jul 9, 2019

Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof

MACROGENICS INC5 citations73

Showing the top 50 of 86 patents by PatentIndex Score.

MACROGENICS INC

Top patents by PatentIndex Score

Humanized FcγRIIB-specific antibodies and methods of use thereof

Identification and engineering of antibodies with variant Fc regions and methods of using same

Identification and engineering of antibodies with variant Fc regions and methods of using same

Humanized FcγRIIB-specific antibodies and methods of use thereof

FcγRIIB fusion proteins and compositions thereof

FcγRIIB specific antibodies and methods of use thereof

Identification and engineering of antibodies with variant Fc regions and methods of using same

CD16A binding proteins and use for the treatment of immune disorders

FcγRIIB specific antibodies and methods of use thereof

Dual expression vector system for antibody expression in bacterial and mammalian cells

Bi-specific monovalent diabodies that are capable of binding CD123 and CD3, and uses thereof

PD-1-binding molecules and methods of use thereof

Covalently bonded diabodies having immunoreactivity with PD-1 and LAG-3, and methods of use thereof

Humanized antibodies against West Nile Virus and therapeutic and prophylactic uses thereof

Multi-chain polypeptide-containing tri-specific binding molecules

HER2/neu-specific antibodies and methods of using same

HER2/neu-specific antibodies and methods of using the same

Identification and engineering of antibodies with variant Fc regions and methods of using same

CD16A binding proteins and use for the treatment of immune disorders

TES7 and antibodies that bind thereto

CD16A binding proteins and use for the treatment of immune disorders

Engineering Fc Antibody regions to confer effector function

PD-1-binding molecules and methods of use thereof

HER2/neu-specific antibodies and methods of using same

Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting

Multi-chain polypeptide-containing tri-specific binding molecules that specifically bind to multiple cancer antigens

CD3-binding molecules capable of binding to human and non-human CD3

Covalent diabodies and uses thereof

Methods for the treatment of disease using immunoglobulins having Fc Regions with altered affinities for FcγRactivating and FcγRinhibiting

BCR-complex-specific antibodies and methods of using same

Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof

HER2/neu-specific antibodies and methods of using same

BCR-complex-specific antibodies and methods of using same

Bi-specific monovalent diabodies that are capable of binding CD123 and CD3, and uses thereof

Antibodies reactive with B7-H3 and uses thereof

Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof

Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof

Antibodies reactive with B7-H3 and uses thereof

Dual expression vector system for antibody expression in bacterial and mammalian cells

Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof

Antibodies that bind to EphA2 and methods of use thereof

LAG-3-binding molecules and methods of use thereof

Variant CD3-binding domains and their use in combination therapies for the treatment of disease

Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof

CD3-binding molecules capable of binding to human and non-human CD3

Covalently bonded diabodies having immunoreactivity with PD-1 and LAG-3, and methods of use thereof

LAG-3-binding molecules and methods of use thereof

Bi-specific monovalent diabodies that are capable of binding CD19 and CD3, and uses thereof

BCR-complex-specific antibodies and methods of using same

Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof